Phase 2 N=64 ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Phase 1: Number of Dose Limiting Toxicities — 3; 0; 0; 0 Dose Limiting Toxicities
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer
Recurrent Cervical Cancer · Stage IIIA Cervical Cancer · Stage IIIB Cervical Cancer
Primary: Progression-free Survival — 2.5 Months
Phase 2 N=55 Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant
Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants Achieved Complete Response (CR) — 3; 9; 16 Participants
Phase 2 N=43 Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7 · Stage IB Breast Cancer AJCC v7
Primary: Number of Participants With Residual Disease — 24 Participants
Phase 2 N=73 Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
Phase 2 N=26 Effects of DHEA in Pulmonary Hypertension
Pulmonary Arterial Hypertension
Primary: Change in Right Ventricular (RV) Longitudinal Strain, % Cardiac Magnetic Resonance Imaging (MRI) — -16.8; -16.9; -17.7; -18.3 % Change in RV Longitudinal Strain — p=0.83
Phase 2 N=40 A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Overall Response Rate (ORR), Central Independent Review Assessed by RECIST v1.1 — 75 Percentage (%) of responders
Phase 2 N=41 Dupilumab in Eosinophilic Gastritis
Eosinophilic Gastritis · Eosinophilic Gastroenteritis
Primary: Relative Change of Peak Eosinophil Counts in the Stomach — -50.28; -3.54 Eosinophil per HPF (EOS/HPF)
Phase 2 N=13 Effect of Endotoxin on Alcohol Consumption
Alcohol Use Disorder
Primary: Alcohol Consumption — 37.57; 50.08 Milliliters
Phase 2 N=33 Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Gliomas
Primary: Overall Response Rate — 9 percent
Phase 2 N=20 Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
Recurrent Chronic Lymphocytic Leukemia · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Follicular Lymphoma
Primary: Best Overall Response Rate (ORR) — 2 Participants
Phase 2 N=76 Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
Primary: The ACR CRISS Composite Score (0-1) at Week 52 — 0.8537; 0.8502 scores on ascale
Phase 2 N=36 Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Carcinoid Syndrome · Carcinoid · Carcinoid Tumor
Primary: Safety - Incidence of Treatment-emergent Adverse Events (TEAEs) — 16; 15; 10; 9 participants
Phase 2 N=496 A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
Early-stage Parkinson's Disease
Primary: Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I-III Sum Score at Day 0 — 34.0; 33.9; 30.6 score on a scale
Phase 2 N=10 EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions
Herpes Simplex Oral
Primary: Duration (Days) of Herpes Labialis Outbreak Until Healed — 10.6; 8.25 days